Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.45 USD | +2.51% | -0.41% | +38.42% |
Business Summary
Number of employees: 52
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Adeno-Associated Viruses-based Gene Therapies
100.0
%
| 3 | 100.0 % | 15 | 100.0 % | +517.55% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 3 | 100.0 % | 15 | 100.0 % | +517.55% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Sean Nolan
CEO | Chief Executive Officer | 56 | 01/20/01 |
Kamran Alam
DFI | Director of Finance/CFO | 46 | 01/20/01 |
President | 58 | 01/20/01 | |
Fred Porter
CTO | Chief Tech/Sci/R&D Officer | - | - |
Jim Rouse
CTO | Chief Tech/Sci/R&D Officer | - | - |
Sean McAuliffe
PRN | Corporate Officer/Principal | - | 01/20/01 |
Emily McGinnis
LAW | General Counsel | - | 01/20/01 |
Tracy M. Porter
HRO | Human Resources Officer | - | 26/21/26 |
Mary Newman
PRN | Corporate Officer/Principal | 65 | 13/21/13 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Philip Donenberg
BRD | Director/Board Member | 63 | 31/20/31 |
Sean Nolan
CEO | Chief Executive Officer | 56 | 01/20/01 |
Sean Stalfort
BRD | Director/Board Member | 54 | 21/23/21 |
President | 58 | 01/20/01 | |
Director/Board Member | 63 | 23/20/23 | |
Alison Long
BRD | Director/Board Member | - | 01/11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 187,018,275 | 140,693,475 ( 75.23 %) | 0 | 75.23 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.42% | 447M | |
+1.77% | 42.75B | |
+47.70% | 41.61B | |
+12.24% | 41.34B | |
-8.83% | 26.59B | |
+7.44% | 25.49B | |
-23.01% | 18.12B | |
+30.56% | 12.24B | |
-1.82% | 11.76B | |
+8.35% | 11B |
- Stock Market
- Equities
- TSHA Stock
- Company Taysha Gene Therapies, Inc.